245 related articles for article (PubMed ID: 22234252)
1. Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults.
Khaled SK; Thomas SH; Forman SJ
Curr Opin Oncol; 2012 Mar; 24(2):182-90. PubMed ID: 22234252
[TBL] [Abstract][Full Text] [Related]
2. Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Aldoss I; Stiller T; Cao TM; Palmer JM; Thomas SH; Forman SJ; Pullarkat V
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1326-9. PubMed ID: 25842050
[TBL] [Abstract][Full Text] [Related]
3. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.
Ram R; Storb R; Sandmaier BM; Maloney DG; Woolfrey A; Flowers ME; Maris MB; Laport GG; Chauncey TR; Lange T; Langston AA; Storer B; Georges GE
Haematologica; 2011 Aug; 96(8):1113-20. PubMed ID: 21508120
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xie M; Shi T; Jiang Q; Jia Y; Zhou D; Tong H; Jin J; Zhu HH
Cancer; 2023 May; 129(10):1523-1536. PubMed ID: 36882308
[TBL] [Abstract][Full Text] [Related]
5. The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Zhang Y; Feng S
Leuk Res; 2021 Oct; 109():106647. PubMed ID: 34325192
[TBL] [Abstract][Full Text] [Related]
6. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
[TBL] [Abstract][Full Text] [Related]
7. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease.
Bourlon C; Lacayo-Leñero D; Inclán-Alarcón SI; Demichelis-Gómez R
Curr Oncol Rep; 2018 Mar; 20(4):36. PubMed ID: 29577208
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
Hwang YY; Mohty M; Chim CS
Hematology; 2015 Mar; 20(2):61-71. PubMed ID: 24993587
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
Brissot E; Labopin M; Beckers MM; Socié G; Rambaldi A; Volin L; Finke J; Lenhoff S; Kröger N; Ossenkoppele GJ; Craddock CF; Yakoub-Agha I; Gürman G; Russell NH; Aljurf M; Potter MN; Nagler A; Ottmann O; Cornelissen JJ; Esteve J; Mohty M
Haematologica; 2015 Mar; 100(3):392-9. PubMed ID: 25527562
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Czyz A; Lewandowski K; Kroll R; Komarnicki M
Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
[TBL] [Abstract][Full Text] [Related]
13. Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis.
Zeng Q; Xiang B; Liu Z
Cancer Med; 2021 Dec; 10(24):8741-8753. PubMed ID: 34761879
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.
Yoon JH; Min GJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
Cancer; 2019 Mar; 125(6):873-883. PubMed ID: 30521062
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia.
Fielding AK; Goldstone AH
Bone Marrow Transplant; 2008 Mar; 41(5):447-53. PubMed ID: 17968326
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cell transplant in adults with acute lymphoblastic leukemia: the present state.
Saadeh SS; Litzow MR
Expert Rev Hematol; 2018 Mar; 11(3):195-207. PubMed ID: 29376437
[TBL] [Abstract][Full Text] [Related]
17. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
18. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
19. Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT.
Akahoshi Y; Nishiwaki S; Arai Y; Harada K; Najima Y; Kanda Y; Shono K; Ota S; Fukuda T; Uchida N; Shiratori S; Tanaka M; Tanaka J; Atsuta Y; Kako S
Bone Marrow Transplant; 2020 Jul; 55(7):1317-1325. PubMed ID: 32447350
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic or preemptive tyrosine kinase inhibitor therapy after allogeneic hematopoietic cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Nakasone H
Int J Hematol; 2023 Aug; 118(2):183-192. PubMed ID: 36807259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]